Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 1,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Not listed Not applicable Interventional

Quantifying Viral Load in Respiratory Particles That Are Generated by Children and Adults With COVID-19 Infection

NCT05195229
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Aerosol Collection
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

NCT04630756
View directory record Official record
Conditions
Advanced Haematological Malignancies
Interventions
AZD4573, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

NCT02254993
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 31, 2026, 5:17 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Tooth Erosion in People With Esophagogastric Cancer

NCT05612048
View directory record Official record
Conditions
Esophagogastric Cancer
Interventions
Survey, Intra-oral camera, Optional Salvia sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed No phase listed Observational

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

NCT02302196
View directory record Official record
Conditions
Cancer of the Breast, Anomaly of Breast
Interventions
Autologous Fat Grafting of the Breast, Control Arm
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Clackamas, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Early Phase 1 Interventional

What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography

NCT01992718
View directory record Official record
Conditions
Uterine Bleeding, Uterine Fibroids, Adenomyosis
Interventions
Evaluation of MRI, US for pelvic and uterine conditions, Patient preference between MRI and Ultrasound
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

University of Georgia Mind Your Heart Pilot Study

NCT07670910
View directory record Official record
Conditions
Hypertension (HTN), Obesity & Overweight
Interventions
Mind Your Heart, DASH Diet Education
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

Low Pressure Pneumoperitoneum and Postoperative Ileus

NCT05344417
View directory record Official record
Conditions
Postoperative Ileus, Gastrointestinal Dysfunction
Interventions
Pneumoperitoneum Pressure, Neuromuscular blockade, Pneumoperitoneum insufflation device, Neuromuscular blockade reversal
Procedure · Device · Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

NCT03088813
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan liposome injection, Topotecan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 31, 2026, 5:17 PM EDT
Completed No phase listed Observational

ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

NCT01891513
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Exercise, ACE inhibitor + exercise, Thiazide diuretic + exercise, Angiotensin receptor blocker + exercise
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 31, 2026, 5:17 PM EDT
Active, not recruiting Phase 1 Interventional

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

NCT04874480
View directory record Official record
Conditions
Recurrent Leukemia, Refractory Leukemia
Interventions
Decitabine, Tegavivint
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Withdrawn Not applicable Interventional

Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients

NCT01169025
View directory record Official record
Conditions
Trauma, Pain
Interventions
Ketamine, Fentanyl
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Mindful Breathing Awareness Through Pursed-Lip Breathing Training

NCT03198780
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Breathing Awareness
Other
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 31, 2026, 5:17 PM EDT
Not yet recruiting No phase listed Observational

Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics

NCT07706140
View directory record Official record
Conditions
Hemoglobin, Cerebral Oxygenation, Congenital Heart Disease
Interventions
Noninvasive hemoglobin monitoring
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional Results available

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982
View directory record Official record
Conditions
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions
ADCT-301, Pembrolizumab
Drug · Biological
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Evaluation of PillCam® Express Capsule Endoscopy Delivery System

NCT01088646
View directory record Official record
Conditions
Small Bowel Disease, Inflammatory Bowel Disease
Interventions
PillCam® Express Capsule Endoscopy Delivery System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
2 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Huntsville, Alabama • Montgomery, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Results available

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

NCT00642941
View directory record Official record
Conditions
Sarcoma
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Post-conditioning to Reduce Infarct Size

NCT00755469
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Post-conditioning
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional Results available

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04543188
View directory record Official record
Conditions
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
Interventions
PF-07284890, Binimetinib, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Orlando, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional

A Personalized Self-Management Program for Older Adults With Chronic Pain and Negative Emotions

NCT03487822
View directory record Official record
Conditions
Pain, Chronic, Negative Emotions
Interventions
Path Pain
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 31, 2026, 5:17 PM EDT